How to exploit stress-related immunity against Hodgkin’s lymphoma

References

• Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29:1812 - 26; http://dx.doi.org/10.1200/JCO.2010.32.8401; PMID: 21483001
   PubMed Web of Science ®Google Scholar
• Montes-Moreno S. Hodgkin’s Lymphomas: a tumor recognized by its microenvironment. Adv Hematol 2011; 2011: 142395; doi: http://dx.doi.org/10.1155/2011/142395; PMID: 20981155.
   Google Scholar
• Carbone A, Gloghini A, Cabras A, Elia G. The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol 2009; 145:468 - 80; http://dx.doi.org/10.1111/j.1365-2141.2009.07651.x; PMID: 19344401
   PubMed Web of Science ®Google Scholar
• Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest 2012; 122:3439 - 47; http://dx.doi.org/10.1172/JCI61245; PMID: 23023715
   PubMed Web of Science ®Google Scholar
• Catellani S, Poggi A, Bruzzone A, Dadati P, Ravetti J-L, Gobbi M, Zocchi MR. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood 2007; 109:2078 - 85; http://dx.doi.org/10.1182/blood-2006-06-028985; PMID: 16973957
   PubMed Web of Science ®Google Scholar
• Zocchi MR, Catellani S, Canevali P, Tavella S, Garuti A, Villaggio B, Zunino A, Gobbi M, Fraternali-Orcioni G, Kunkl A, et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood 2012; 119:1479 - 89; http://dx.doi.org/10.1182/blood-2011-07-370841; PMID: 22167753
   PubMed Web of Science ®Google Scholar
• Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 2009; 31:184 - 96; http://dx.doi.org/10.1016/j.immuni.2009.08.006; PMID: 19699170
   PubMed Web of Science ®Google Scholar
• Bonneville M, O’Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10:467 - 78; http://dx.doi.org/10.1038/nri2781; PMID: 20539306
   PubMed Web of Science ®Google Scholar
• Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8:279 - 89; http://dx.doi.org/10.1038/nri2215; PMID: 18340345
   PubMed Web of Science ®Google Scholar
• Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27:5944 - 58; http://dx.doi.org/10.1038/onc.2008.272; PMID: 18836475
   PubMed Web of Science ®Google Scholar
• Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 210; 235(1): 267-85; doi: http://dx.doi.org/10.1111/j.0105-2896.2010.00893.x; PMID: 20536569.
   Google Scholar
• González S, López-Soto A, Suarez-Alvarez B, López-Vázquez A, López-Larrea C. NKG2D ligands: key targets of the immune response. Trends Immunol 2008; 29:397 - 403; http://dx.doi.org/10.1016/j.it.2008.04.007; PMID: 18602338
   PubMed Web of Science ®Google Scholar
• Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002; 23:14 - 8; http://dx.doi.org/10.1016/S1471-4906(01)02110-X; PMID: 11801449
   PubMed Web of Science ®Google Scholar
• Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389 - 96; http://dx.doi.org/10.1182/blood-2003-01-0019; PMID: 12714493
   PubMed Web of Science ®Google Scholar
• Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, Steinle A, Ghia P, Stella S, Caligaris-Cappio F, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004; 64:9172 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-04-2417; PMID: 15604289
   PubMed Web of Science ®Google Scholar
• Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009; 23:641 - 8; http://dx.doi.org/10.1038/leu.2008.354; PMID: 19151770
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734 - 8; http://dx.doi.org/10.1038/nature01112; PMID: 12384702
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66:2520 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-05-2520; PMID: 16510567
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102:200 - 6; http://dx.doi.org/10.1182/blood-2002-12-3665; PMID: 12623838
   PubMed Web of Science ®Google Scholar
• Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, Diefenbach A, Yagita H, Godfrey DI, Smyth MJ. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 2004; 199:879 - 84; http://dx.doi.org/10.1084/jem.20031981; PMID: 15007091
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res 2007; 67:5 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-06-3069; PMID: 17210676
   PubMed Web of Science ®Google Scholar
• Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, Fournié JJ. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 1994; 264:267 - 70; http://dx.doi.org/10.1126/science.8146660; PMID: 8146660
   PubMed Web of Science ®Google Scholar
• Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197:163 - 8; http://dx.doi.org/10.1084/jem.20021500; PMID: 12538656
   PubMed Web of Science ®Google Scholar
• Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 2007; 215:59 - 76; http://dx.doi.org/10.1111/j.1600-065X.2006.00479.x; PMID: 17291279
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999; 340:737 - 8; http://dx.doi.org/10.1056/NEJM199903043400914; PMID: 10068336
   PubMed Web of Science ®Google Scholar
• Moss ML, Bartsch JW. Therapeutic benefits from targeting of ADAM family members. Biochemistry 2004; 43:7227 - 35; http://dx.doi.org/10.1021/bi049677f; PMID: 15182168
   PubMed Web of Science ®Google Scholar
• Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6:32 - 43; http://dx.doi.org/10.1038/nrm1548; PMID: 15688065
   PubMed Web of Science ®Google Scholar
• Smalley DM, Ley K. L-selectin: mechanisms and physiological significance of ectodomain cleavage. J Cell Mol Med 2005; 9:255 - 66; http://dx.doi.org/10.1111/j.1582-4934.2005.tb00354.x; PMID: 15963248
   PubMed Web of Science ®Google Scholar
• Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95:930 - 5; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03179.x; PMID: 15596040
   PubMed Web of Science ®Google Scholar
• Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochim Biophys Acta 2004; 1699:35 - 44; http://dx.doi.org/10.1016/j.bbapap.2004.02.017; PMID: 15158710
   PubMed Web of Science ®Google Scholar
• Gruber CW, Cemazar M, Heras B, Martin JL, Craik DJ. Protein disulfide isomerase: the structure of oxidative folding. Trends Biochem Sciences 2006; 31(8): 455–64; doi:http://dx.doi.org/10.1016/j.tibs.2006.06.001; P MID 16815710.
   Google Scholar
• Hatahet F, Ruddock LW. Substrate recognition by the protein disulfide isomerases. FEBS J 2007; 274:5223 - 34; http://dx.doi.org/10.1111/j.1742-4658.2007.06058.x; PMID: 17892489
   PubMed Web of Science ®Google Scholar
• Hatahet F, Ruddock LW. Protein disulfide isomerase: a critical evaluation of its function in disulfide bond formation. Antioxid Redox Signal 2009; 11:2807 - 50; http://dx.doi.org/10.1089/ars.2009.2466; PMID: 19476414
   PubMed Web of Science ®Google Scholar
• Escrevente C, Morais VA, Keller S, Soares CM, Altevogt P, Costa J. Functional role of N-glycosylation from ADAM10 in processing, localization and activity of the enzyme. Biochim Biophys Acta 2008; 1780:905 - 13; http://dx.doi.org/10.1016/j.bbagen.2008.03.004; PMID: 18381078
   PubMed Web of Science ®Google Scholar
• Rzymski T, Petry A, Kračun D, Rieß F, Pike L, Harris AL, Görlach A. The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene 2012; 31:3621 - 34; http://dx.doi.org/10.1038/onc.2011.522; PMID: 22105359
   PubMed Web of Science ®Google Scholar
• Kaiser BK, Yim D, Chow I-T, Gonzalez S, Dai Z, Mann HH, Strong RK, Groh V, Spies T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007; 447:482 - 6; http://dx.doi.org/10.1038/nature05768; PMID: 17495932
   PubMed Web of Science ®Google Scholar
• Huergo-Zapico L, Gonzalez-Rodriguez AP, Contesti J, Gonzalez E, López-Soto A, Fernandez-Guizan A, Acebes-Huerta A, de Los Toyos JR, Lopez-Larrea C, Groh V, et al. Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. Cancer Immunol Immunother 2012; 61:1201 - 10; http://dx.doi.org/10.1007/s00262-011-1195-z; PMID: 22215138
   PubMed Web of Science ®Google Scholar
• Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A 2008; 105:1285 - 90; http://dx.doi.org/10.1073/pnas.0711293105; PMID: 18202175
   PubMed Web of Science ®Google Scholar
• Fonseca C, Soiffer R, Ho V, Vanneman M, Jinushi M, Ritz J, Neuberg D, Stone R, DeAngelo D, Dranoff G. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood 2009; 113:1681 - 8; http://dx.doi.org/10.1182/blood-2007-09-114157; PMID: 19008459
   PubMed Web of Science ®Google Scholar
• Nückel H, Switala M, Sellmann L, Horn PA, Dürig J, Dührsen U, Küppers R, Grosse-Wilde H, Rebmann V. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010; 24:1152 - 9; http://dx.doi.org/10.1038/leu.2010.74; PMID: 20428196
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008; 68:6368 - 76; http://dx.doi.org/10.1158/0008-5472.CAN-07-6768; PMID: 18676862
   PubMed Web of Science ®Google Scholar
• Fernández-Messina L, Ashiru O, Boutet P, Agüera-González S, Skepper JN, Reyburn HT, Valés-Gómez M. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 2010; 285:8543 - 51; http://dx.doi.org/10.1074/jbc.M109.045906; PMID: 20080967
   PubMed Web of Science ®Google Scholar
• Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172:7335 - 40; PMID: 15187109
   PubMed Web of Science ®Google Scholar
• Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K, Kanto T, Hiramatsu N, Hayashi N. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009; 69:8050 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-09-0789; PMID: 19826051
   PubMed Web of Science ®Google Scholar
• Wu JD, Atteridge CL, Wang X, Seya T, Plymate SR. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res 2009; 15:632 - 40; http://dx.doi.org/10.1158/1078-0432.CCR-08-1305; PMID: 19147769
   PubMed Web of Science ®Google Scholar
• Wang X, Lundgren AD, Singh P, Goodlett DR, Plymate SR, Wu JD. An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding. Biochem Biophys Res Commun 2009; 387:476 - 81; http://dx.doi.org/10.1016/j.bbrc.2009.07.062; PMID: 19615970
   PubMed Web of Science ®Google Scholar
• Rossello A, Nuti E, Orlandini E, Carelli P, Rapposelli S, Macchia M, Minutolo F, Carbonaro L, Albini A, Benelli R, et al. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg Med Chem 2004; 12:2441 - 50; http://dx.doi.org/10.1016/j.bmc.2004.01.047; PMID: 15080939
   PubMed Web of Science ®Google Scholar
• Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, et al. Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. J Med Chem 2009; 52:6347 - 61; http://dx.doi.org/10.1021/jm900335a; PMID: 19775099
   PubMed Web of Science ®Google Scholar
• Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, et al. Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models. [PMID] J Med Chem 2010; 53:2622 - 35; http://dx.doi.org/10.1021/jm901868z; PMID: 20180536
   PubMed Web of Science ®Google Scholar
• Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, Krause H, Agathanggelou A, Niedobitek G, Stein H. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin’s disease. Blood 1996; 87:2918 - 29; PMID: 8639912
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99:4283 - 97; http://dx.doi.org/10.1182/blood-2002-01-0099; PMID: 12036854
   PubMed Web of Science ®Google Scholar
• Poggi A, Zancolli M, Boero S, Catellani S, Musso A, Zocchi MR. Differential survival of γδT cells, αβT cells and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells. Int J Cancer 2011; 129:387 - 96; http://dx.doi.org/10.1002/ijc.25682; PMID: 20853320
   PubMed Web of Science ®Google Scholar
• Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103:1755 - 62; http://dx.doi.org/10.1182/blood-2003-07-2594; PMID: 14604957
   PubMed Web of Science ®Google Scholar
• Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65:6321 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-04-4252; PMID: 16024634
   PubMed Web of Science ®Google Scholar
• Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008; 111:1428 - 36; http://dx.doi.org/10.1182/blood-2007-07-101311; PMID: 17993609
   PubMed Web of Science ®Google Scholar
• Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT. Proteasome regulation of ULBP1 transcription. J Immunol 2009; 182:6600 - 9; http://dx.doi.org/10.4049/jimmunol.0801214; PMID: 19414815
   PubMed Web of Science ®Google Scholar
• Richards FM, Tape CJ, Jodrell DI, Murphy G. Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One 2012; 7:e40597; http://dx.doi.org/10.1371/journal.pone.0040597; PMID: 22792380
   PubMedGoogle Scholar
• Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004; 64:7596 - 603; http://dx.doi.org/10.1158/0008-5472.CAN-04-1627; PMID: 15492287
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96:384 - 92; PMID: 10887096
   PubMed Web of Science ®Google Scholar
• Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102:2310 - 1; http://dx.doi.org/10.1182/blood-2003-05-1655; PMID: 12959943
   PubMed Web of Science ®Google Scholar
• Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M, Castella B, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005; 19:664 - 70; PMID: 15744346
   PubMed Web of Science ®Google Scholar
• Capietto A-H, Martinet L, Cendron D, Fruchon S, Pont F, Fournié JJ. Phosphoantigens overcome human TCRVgamma9+ gammadelta Cell immunosuppression by TGF-beta: relevance for cancer immunotherapy. J Immunol 2010; 184:6680 - 7; http://dx.doi.org/10.4049/jimmunol.1000681; PMID: 20483742
   PubMed Web of Science ®Google Scholar
• Chiplunkar S, Dhar S, Wesch D, Kabelitz D. gammadelta T cells in cancer immunotherapy: current status and future prospects. Immunotherapy 2009; 1:663 - 78; http://dx.doi.org/10.2217/imt.09.27; PMID: 20635991
   PubMed Web of Science ®Google Scholar